INTERESTING COMPANIES FOUND
FLX Bio (2015, SF, $79M) – Developing a dual inhibitor targeting CDK4/6 and FLT3 kinase for the treatment of acute myeloid leukemia (AML). Backed by Column Group, Topspin Partners, KPCB and Celgene. Link
Ideaya Biosciences (2015, SF, $46M) – Developing synthetic lethality medicines targeting DNA damage and repair to treat cancer.5AM incubated company which is backed by Celgene, Novartis, ARE, Wuxi Ventures and Canaan Partners. Link
HIGHLIGHTS OF THE DAY
- FDA approves Vaxchora, PaxVax’s single-dose oral Cholera vaccine. Read More
- Paratek shares climb after Antibiotic clears first Phase 3 hurdle. Read More
- Alcresta raises $49M in Series C financing for digestive enzyme launch. Read More
- Merck soars as Keytruda impresses in late-stage Lung Cancer study. Read More